Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Bitcoin faces $58K test as U.S. demand cracks – What’s next for BTC?

Bitcoin faces $58K test as U.S. demand cracks – What’s next for BTC?

AMBCryptoAMBCrypto2026/07/01 07:01
By:AMBCrypto

Bitcoin’s [BTC] rally is losing strength. For much of history, American capital has been one of the biggest drivers of BTC; now, that’s not the case.

With ETFs bleeding in addition, is the market set for chaos?

U.S. Bitcoin demand loses strength

One key metric to keep an eye on is the U.S. to The Rest Reserve Ratio, which compares Bitcoin held by U.S. entities with the rest of the world. After rising in strength through this cycle, the ratio has now fallen from its recent peak near 1.79 to around 1.59.

AD

Because U.S. capital is a major force behind Bitcoin’s rally, BTC is struggling to hold when this demand falls. Interestingly, this ratio was going weak before BTC price started to.

The first cryptocurrency will most certainly face resistance and more downside pressure, unless U.S. demand starts recovering.

Spot ETF outflows confirm the fall

After months of green, the ETF trend has now flipped. The latest monthly net flow saw a huge outflow of around $4.29 billion. Considering ETFs were one of the clearest signs of institutional buying during rallies, this is concerning.

When ETF demand was strong, BTC found steady support. But now, with two weak months, the market looks nervous.

Price tests $58K support

Bitcoin slipped below the $60K area and was trading close to $58,500 at the time of writing. Sellers were very much still in control. The RSI was near the oversold zone, so the market is under pressure. However, we’re not ready for a big bounce yet.

Pace has not gone back in favor of the buyers. A short relief move is possible after this decline, but greater picture is still unclear. Unless BTC makes it back to the $60-$62K range, a bigger fall to lower support levels is possible.

Final Summary

  • U.S. demand for Bitcoin is weakening, with Spot ETF outflows reaching $4.29 billion. This signals reduced investor confidence.
  • Bitcoin is struggling to hold the $58K support zone, while the U.S. reserve ratio has dropped to 1.59 – reinforcing downside risks.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales